Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
In Vitro Diagnostics Coronavirus COVID-19 Diagnostics

AACC 2020: Roche Panel Discusses How Pandemic Ushered In New Era For Diagnostics Ecosystem

  • Analysis

Executive Summary

A panel of experts, including the CEO of Roche Diagnostics, discussed how the pandemic will lead to a ”reimagining” of diagnostics, expanding access for testing with at-home testing and virtual care.

You may also be interested in...



Abbott Receives US Authorization For First 'Virtually Guided' At-Home Rapid Test

Abbott plans to deliver 30 million BinaxNOW prescription, at-home rapid tests in the first quarter of 2021; 90 million more in the second quarter.

COVID-19 Testing Boosts Roche Diagnostics Sales In H1

Roche's diagnostics division grew 3% in the first half of 2020 with exploding demand for COVID-19 tests offsetting declines in routine testing.

FDA Grants EUA For Roche’s Coronavirus Antibody Test

The company says the serology test has a specificity of 99.8% and sensitivity of 100%

Table

View full table

Topics

Related Companies

Tags:
In Vitro Diagnostics Coronavirus COVID-19 Diagnostics
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT143222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By